The European Society of Cardiology (ESC) is a not-for-profit professional medical association that advances cardiovascular science and patient care across Europe and internationally. Headquartered in Sophia Antipolis, France, it brings together clinicians, researchers, and allied professionals to improve prevention, diagnosis, and treatment of cardiovascular disease.
The ESC organizes the annual ESC Congress—one of the world’s largest cardiovascular meetings—and a range of specialty conferences. It publishes leading peer‑reviewed journals, including the European Heart Journal, develops widely used clinical practice guidelines, and runs registries, education, and certification programs to support evidence-based care. While not a chemical manufacturer, the ESC is a key venue for clinical trial results and scientific updates relevant to the healthcare and life sciences sectors.
Pre‑specified VESALIUS‑CV analysis shows evolocumab plus background therapy lowers deaths and major CV events in high‑risk adults without prior MI/stroke.
Wegovy® shows 57% greater risk reduction in heart events vs. tirzepatide in obese patients with CVD. Benefits are specific to semaglutide, not general to GLP-1 or GIP/GLP-1 classes.
Vericiguat didn't reduce primary endpoint risk in HFrEF patients but showed fewer cardiovascular deaths. Safety profile consistent with previous trials.
